1. Introduction
===============

The past several decades have witnessed the uprising of antimicrobial resistance, which mainly caused by abuse of antimicrobials, and witnessed the huge threats to human health that caused by antimicrobial resistance.^\[[@R1]\]^ According to Antibiotic Resistance Threats in the United States 2013 released by Centers for Disease Control and Prevention of United States, about 20%--50% of all antibiotics prescribed in US acute care hospitals are unnecessary or inappropriate. It was reported that antimicrobial resistance was closely related with antimicrobial consumption.^\[[@R2],[@R3]\]^ Operations of hospital based antibiotic stewardship programs in many countries works in reducing rates of antibiotic resistance and the spread of resistant clones.^\[[@R4]--[@R6]\]^ Early in 2004, Southwest hospital, the First Affiliated Hospital of Army Medical University (Third Military Medical University) and one of the largest hospitals in Southwest China, has lunched antimicrobial stewardship programs to explore the relationship between antimicrobial usage and resistance and to further provide an observational experience for guiding prescription and for rational use of antimicrobial.

Of all the bacterial infection, Gram-negative bacteria infections have gotten particular concern because of their features.^\[[@R7],[@R8]\]^ Firstly, the ability of highly efficient up-regulating or acquiring genes that code for mechanisms of antibiotic drug resistance were observed at those organisms, especially in the presence of antibiotic selection pressure. Secondly, multiple mechanisms against the same antibiotic or using a single mechanism to affect multiple antibiotics were also frequently discovered. In the meanwhile, increasing challenges in new compounds screening, high costs and long time for drug development, and growing complexity of designing and performing clinical trials contribute to the growing drug resistance rates, too.^\[[@R9]\]^ At present, rational use of antimicrobial seem to be one the most effective ways to fight against antimicrobial resistance.

The aim of the present study was to evaluate the relationship between antimicrobial use and resistance in a representative sample of Chinese hospital. Particularly, we have applied a time series model for antimicrobial resistance forecasting, which may help in fighting against Gram-negative bacterial antimicrobial resistance in a hospital setting.

2. Methods
==========

2.1. Data source
----------------

The study was conducted at the First Affiliated Hospital of Army Medical University, Chongqing, China, a more than 2900 beds, tertiary care teaching hospital. Antibiotic susceptibility patterns in inpatient isolates were monitored at the Center for Microbiology of Southwest hospital from 2004 to 2018. Given the fact that no data on individual patients were specifically noted, ethics committee involvement was not necessary.

2.2. Data on antimicrobial consumption
--------------------------------------

Consumption data of β-lactamase inhibitor complex, aminoglycosides, quinolones, third-generation cephalosporins, fourth-generation cephalosporin, carbapenems, cephamycins, oxacephems, and sulfonamides were obtained from the hospital computer center database. The data contained the number of packages of each drug used annually from January 2004 to December 2018. DDD was obtained according to WHO anatomical therapeutic chemical (ATC) classification system. DDDs/1000 is shown as DDD per 1000 patient days.

2.3. Data on resistance rates of antimicrobials
-----------------------------------------------

The susceptibility of several selected Gram-negative bacterial to antimicrobial agents was tested using the disk diffusion method according to the guidelines set by Clinical and Laboratory Standards Institute (CLSI, Performance Standards for Antimicrobial Susceptibility Testing, 21st edition). Drug resistance was reported as the percentage of resistant isolates (percentage of all resistant and intermediate resistant strains) among all tested isolates. *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853, and *Klebsiella pneumoniae* ATCC70063 were taken as reference strains to ensure reproducibility of the antibiotic susceptibility testing procedure.

2.4. Statistical Analysis
-------------------------

The primary forecasting analysis of resistance rate data of antimicrobial were performed by ARIMA.^\[[@R10]--[@R13]\]^ This model is justified for analysis of equidistant and discrete samples of data in a time series model, which suits perfectly with the analysis of resistance rate data of antimicrobial. Consisting of autoregressive (AR), moving average (MA), and ARMA models, ARIMA model was set up through three major steps: identification, estimation and diagnosis. Briefly, an ARIMA model were firstly created based on observed annual antimicrobial consumption and resistance rate and differencing were performed for achieving stationarity when necessary. Then, AR, MA, and ARMA were identified by detecting the series autocorrelation function (ACF) and partial autocorrelation function (PACF). Unconditional least squares or likelihood functions were used for estimating the parameters of the identified model. The best model was chosen based on a combination of lowest criterion of Akaike information, Bayesian information and root mean square error from each AR-MA combination. Once the model was set up, the prevalence was forecasted by stimulating projected to 2021 and 95% confidence interval (CI) were calculated from the standard deviation. Analyses were performed using STATA version 14.2 and data processed by GraphPad Prism version 7.0.

Association between antimicrobial consumption and antimicrobials resistance was evaluated by parametric Pearson\'s correlation coefficient. Pearson correlation coefficient γ \> 0.6 or γ \< −0.6 with a *P* value \< .05 was considered statistically significant.

3. Results
==========

3.1. Antimicrobial consumption
------------------------------

As for the 9 major classes of antimicrobial consumption from 2004 to 2018, the consumption of carbapenem went up yearly while the consumption of quinolones and aminoglycosides went opposite, generally. The consumption of third and fourth generation cephalosporins, cephamycins, and β-lactamase inhibitors went with an irregular up and down (Figure [1](#F1){ref-type="fig"}).

![Consumptions of 9 major classes of antimicrobial from 2004 to 2018 in Southwest Hospital.](medi-98-e17157-g001){#F1}

As for the 8 key antimicrobial (imipenem, meropenem, ceftazidime, levofloxacin, moxifloxacin, etimicin, amikacin, cefixime) monitored in the hospital, consumption of imipenem and meropenem went up year by year while the consumption of levofloxacin went opposite; consumption of cefixime first went through an increase and then decrease while consumption of ceftazidime down first and then down from 2004 to 2018 (Figure [2](#F2){ref-type="fig"}). The year of 2010 is a turning point of antimicrobial consumption, no matter 9 major classes of antimicrobial or the key monitored antimicrobial, for the policy of national special rectification on clinical use of antibacterial drugs released in 2010.
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3.2. Correlation between antimicrobial consumption and antimicrobial resistance
-------------------------------------------------------------------------------

As present in Figure [3](#F3){ref-type="fig"}, for specific bacterial resistance rate changes from 2004 to 2018, we can find out that the resistance rate of levofloxacin to *E. coli* was high all along. Additionally, the resistance rate of imipenem to *Acinetobacter baumannii* and to *K. pneumoniae* are on the rising while resistance rate of amikacin to *Enterobacter cloacae,* imipenem to *P. aeruginosa* and ceftazidime to *K. pneumoniae* decrease yearly from 2004 to 2018, in general.
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Based on the Pearson\'s correlation coefficient analysis (Table [1](#T1){ref-type="table"}), the resistance rate of levofloxacin resistance *E. coli*, ceftazidime resistance *K. pneumoniae*, amikacin resistant *E. cloacae*, imipenem resistance *P. aeruginosa* have a significant positive relationship with consumption of aminoglycosides and quinolone and a negative relationship with consumption of carbapenem (γ = 0.618, *P* = .024; γ = 0.609, *P* = .027; γ = 0.772, *P* = .002; γ = 0.916, *P* = .0001, respectively for aminoglycosides. γ = 0.732, *P* = .004; γ = 0.844, *P* = .0001; γ = 0.795, *P* = .001; γ = 0.818, *P* = .001, respectively for quinolone; γ = −0.659, *P* = .014; γ = −0.784, *P* = .002; γ = −0.921, *P* = .0001; γ = −0.860, *P* = .0001, respectively for carbapenem). Resistance rate of imipenem resistance *A. baumannii* has a significant positive relationship with consumption of carbapenem and a negative relationship with consumption of aminoglycosides and quinolone (γ = 0.954, *P* = .0001, for carbapenem; γ = −0.811, *P* = .001, for aminoglycosides; γ = −0.864, *P* = 0.0001, for quinolone.). Resistance rate of levofloxacin resistance *E. coli* has a significant positive relationship with consumption of β-lactamase inhibitor combinations and oxacephems (γ = 0.620, *P* = .024; γ = 0.724, *P* = .005, respectively). Resistance rate of imipenem resistance *P. aeruginosa* has a significant positive relationship with consumption of β-lactamase inhibitor combinations, oxacephems and sulfonamides (γ = 0.715, *P* = .006; γ = 0.720, *P* = .006;γ = 0.691, *P* = .009, respectively).
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Relationship between yearly consumption of 9 classes of antimicrobial agents and rates of 6 key resistant Gram-negative pathogens at Southwest Hospital from 2004 to 2018.
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3.3. Prediction of antimicrobial resistance by ARIMA
----------------------------------------------------

Complicated but traceable relationships between antimicrobial consumption and antimicrobial resistance were observed. In this setting, a modeling for predicting the prevalence of antimicrobial resistance would be of great importance in preventing and controlling the spread of drug resistance. ARIMA is particularly fitted to time series data either to better understand the data or to predict future points in the series, which is perfect in predicting antimicrobial resistance under our current data setting.^\[[@R10]--[@R13]\]^ We applied ARIMA to predict resistance rate of *A. baumannii* to imipenem, *E. coli* to levofloxacin and *K. pneumoniae* to imipenem for the upcoming 2019 to 2021 based on antimicrobial consumption and antimicrobial resistance we got from 2004 to 2018. From our prediction, resistance rate of *A. baumannii* to imipenem will rise form 3.3% to 63.8% (Figure [4](#F4){ref-type="fig"}); resistance rate of *K. pneumoniae* to imipenem will rise form 0% to 8.5% (Figure [5](#F5){ref-type="fig"}); resistance rate of *E. coli* to levofloxacin will stay at around 59.80% in 2021 (Figure [6](#F6){ref-type="fig"}).

![Prediction of resistance rate of imipenem to *Acinetobacter baumannii* by ARIMA.](medi-98-e17157-g005){#F4}

![Prediction of resistance rate of imipenem to *Klebsiella pneumoniae* by ARIMA.](medi-98-e17157-g006){#F5}

![Prediction of resistance rate of levofloxacin to *Escherichia coli* by ARIMA.](medi-98-e17157-g007){#F6}

4. Discussion
=============

The present study firstly revealed that even though the consumption β-lactamase inhibitor complex and third and fourth generation cephalosporins fluctuations, and the usage of quinolones decreases year by year, the usage of all the mentioned antimicrobial are still at very high level even in 2018, which can partly be reflected by the resistance rate of *E. coli* to levofloxacin (fluctuates around 55% from 2004 to 2018). Additionally, we found multiple direct relationships between several antimicrobial consumption and antimicrobial resistance in some Gram-negative bacteria. Of all the direct relationships between antimicrobial consumption and antimicrobial resistance, one is of our particular interest: consumption of β-lactamase inhibitor combinations has a significant positive relationship with *P. aeruginosa* resistance to imipenem (γ = 0.715, *P* = .006). Similar findings were also reported by other groups.^\[[@R14],[@R15]\]^ We speculated that the *P. aeruginosa* resistance to imipenem could also be induced by the overuse of β-lactamase inhibitor combinations. We then hypothesized that the β-lactamase inhibitor combinations induced *P. aeruginosa* resistance to imipenem could cause the same cell wall stress so that to promotes the development of drug resistance as imipenem does.^\[[@R16],[@R17]\]^ However, this hypothesis remains to be clarified in the upcoming future.

Another interesting phenomenon is that although resistance rate of imipenem resistance *K. pneumoniae* have no significant relationship with consumption of carbapenem on our current setting (γ = 0.572, *P* = .041), relationship between those two would be statistically different when we only taken data from 2011 to 2018 (γ = 0.950, *P* \< .01). In parallel with our data, data from India also found that the resistance rate of *K. pneumoniae* was significantly positive related to consumption of meropenem from 2010 to 2013.^\[[@R18]\]^ Giving the fact that consumption of carbapenem rises yearly, it is really critical to keep carbapenem related bacterial resistance under close surveillance. ARIMA prediction on resistance rate of selected bacterial to imipenem also provides the same warning.

To our knowledge, the present study, which highlighted the relationship between 9 classes of antimicrobial consumption and 6 Gram-negative bacterial resistance, presents one of the largest and longest antimicrobial databases in China. With a database of such scale and a suitable method like ARIMA, the prediction of antimicrobial resistance rate would be of great validity and reliability. This positive correlation between antimicrobial consumption and antimicrobial resistance would help guiding the prescription for future antimicrobial resistance control. Future work on multicenter cooperation in digging the database would help us in better controlling the prevalence of antimicrobial resistance.
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